rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2012-8-1-75-80rpcardio-419Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯBETA-BLOCKERS IN THE TREATMENT OF ARTERIAL HYPERTENSION: EVIDENCE BASED DATA AND REAL PRACTICEБЕТА-АДРЕНОБЛОКАТОРЫ В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ: ДАННЫЕ ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЫ И РЕАЛЬНАЯ ПРАКТИКАЛеоноваМ. В.LeonovaM. V.

д.м.н., профессор кафедры клинической фармакологии РНИМУ им. Н.И. Пирогова

anti23@mail.ruРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаРоссияRussian National Research Medical University named after N.I. PirogovRussian Federation201227122015817580Copyright © Leonova M.V., 20152015Леонова М.В.Leonova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/419

Data of the largest meta-analyzes of beta-blockers use in arterial hypertension is presented. The role of beta-blockers among other basic groups of antihypertensive drugs (thiazide diuretics, calcium channel blockers, ACE inhibitors) is evaluated. Special considerations of beta-blockers use in hypertensive patients with diabetes mellitus and chronic heart failure are discussed. Special attention is paid to bisoprolol.

Представлены данные наиболее крупных мета-анализов применения бета-адреноблокаторов (БАБ) при артериальной гипертонии. Оценивается роль БАБ среди других основных групп антигипертензивных препаратов (тиазидные диуретики, антагонисты кальция, ингибиторы АПФ). Рассматриваются особенности применения БАБ при артериальной гипертонии в сочетании с сахарным диабетом и хронической сердечной недостаточностью. Особое внимание уделяется бисопрололу.

бета-адреноблокаторыбисопрололартериальная гипертонияхроническая сердечная недостаточностьсахарный диабетbeta-blockersbisoprololarterial hypertensionchronic heart failurediabetes mellitusReferencesWright J.M., Musini V.M. First-line drugs for hypertension. Cohrane Database Syst Rev 2009;(3):Wright J.M., Musini V.M. First-line drugs for hypertension. Cohrane Database Syst Rev 2009;(3):CD001841.CD001841.Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.Lindholm L.H., Carlberg B., Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-1553.Lindholm L.H., Carlberg B., Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-1553.Bangalore S., Wild D., Parkar S. et al. Beta-blockers for primary prevention of heart failure in patients with hypertension: insights from a meta-analysis. JACC 2008;52:1062-1072.Bangalore S., Wild D., Parkar S. et al. Beta-blockers for primary prevention of heart failure in patients with hypertension: insights from a meta-analysis. JACC 2008;52:1062-1072.Khan N., McAlister F .A. Re-examining the efficacy of b-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006;174(12):1737-1742.Khan N., McAlister F .A. Re-examining the efficacy of b-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006;174(12):1737-1742.Elliott W.J., Meyer P .M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta- analysis. Lancet 2007;369:201–207.Elliott W.J., Meyer P .M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta- analysis. Lancet 2007;369:201–207.Holman R.R., Paul S.K., Bethel M.A. et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-1576.Holman R.R., Paul S.K., Bethel M.A. et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-1576.Shorr R.I., Ray W.A., Daugherty J.R. Griffin M.R. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997;278(1):40-43.Shorr R.I., Ray W.A., Daugherty J.R. Griffin M.R. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997;278(1):40-43.Leonova M.V., Belousov Yu.B., Shteynberg L.L., Galitskiy A.A. Results farmakoepide-miologichesko- go study of hypertension PIFAGOR III (a survey of patients with hypertension). Sistemnye Gipertenzii 2010; (2): 33-39. Russian (Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л., Г алицкий А.А. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР III (опрос пациентов с АГ). Системные Гипертензии 2010; 2: 33-39).Leonova M.V., Belousov Yu.B., Shteynberg L.L., Galitskiy A.A. Results farmakoepide-miologichesko- go study of hypertension PIFAGOR III (a survey of patients with hypertension). Sistemnye Gipertenzii 2010; (2): 33-39. Russian (Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л., Г алицкий А.А. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР III (опрос пациентов с АГ). Системные Гипертензии 2010; 2: 33-39).Carlberg B., Samuelsson O., Lindholm L.H. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-1689.Carlberg B., Samuelsson O., Lindholm L.H. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-1689.Bühler F .R., Berglund G., Anderson O.K. et al. Double-blind comparison of the cardioselective beta- blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986;8 (Suppl 11):S122-127.Bühler F .R., Berglund G., Anderson O.K. et al. Double-blind comparison of the cardioselective beta- blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986;8 (Suppl 11):S122-127.Czuriga I., Riecansky I., Bodnar J. et al. Cardioselective beta-blocker nebivolol with bisoprolol in hy- pertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovascular Drugs and Therapy 2003;17 (3): 257-263.Czuriga I., Riecansky I., Bodnar J. et al. Cardioselective beta-blocker nebivolol with bisoprolol in hy- pertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovascular Drugs and Therapy 2003;17 (3): 257-263.Hiltunen T.P ., Suonsyrjä T., Hannila-Handelberg T. et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens 2007;20(3):311-318.Hiltunen T.P ., Suonsyrjä T., Hannila-Handelberg T. et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens 2007;20(3):311-318.Frithz G. Influence on plasma-insulin and blood-glucose by treatment with bisoprolol in hypertensive, non-diabetic patients. J Clin Basic Cardiol 2001;4:229–230.Frithz G. Influence on plasma-insulin and blood-glucose by treatment with bisoprolol in hypertensive, non-diabetic patients. J Clin Basic Cardiol 2001;4:229–230.Haneda T., Ido A., Fujikane T., Tanaka H. et al. Effect of bisoprolol, a beta 1-selective beta-blocker , on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Jap J Geriatrics 1998;35(1):33-38.Haneda T., Ido A., Fujikane T., Tanaka H. et al. Effect of bisoprolol, a beta 1-selective beta-blocker , on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Jap J Geriatrics 1998;35(1):33-38.Vulpis V., Antonacci A., Prandi P . et al. The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus. Minerva Med 1991;82(4):189- 193.Vulpis V., Antonacci A., Prandi P . et al. The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus. Minerva Med 1991;82(4):189- 193.Wang B., Song W., Liu G. The effect long-term administration of a selective beta1 blocker bisoprolol on glucose metabolism in patients with essential hypertensive and type 2 diabetes mellitus. Chin J Internal Med 2005;44:503-505.Wang B., Song W., Liu G. The effect long-term administration of a selective beta1 blocker bisoprolol on glucose metabolism in patients with essential hypertensive and type 2 diabetes mellitus. Chin J Internal Med 2005;44:503-505.Dominguez L.J., Barbagallo M., Jacober S.J. et al. Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens 1997;10(12 Pt 1):1349-1355.Dominguez L.J., Barbagallo M., Jacober S.J. et al. Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens 1997;10(12 Pt 1):1349-1355.Janka H.U., Ziegler A.G., Disselhoff G., Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol 1986;8 (Sup- pl 11):S96-99.Janka H.U., Ziegler A.G., Disselhoff G., Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol 1986;8 (Sup- pl 11):S96-99.Mychka V.B., Sergienko V.B., Gornostaev V.V. et al. Effect of treatment with bisoprolol on cerebral perfusion in patients with metabolic syndrome. Arterial'naya Gipertenziya 2003; 9(5): 160-163. Russian (Мычка В.Б., Сергиенко В.Б., Г орностаев В.В. и др. Влияние терапии бисопрололом на перфузию головного мозга у больных с метаболическим синдромом. Артериальная Гипертензия 2003; 9(5): 160-163).Mychka V.B., Sergienko V.B., Gornostaev V.V. et al. Effect of treatment with bisoprolol on cerebral perfusion in patients with metabolic syndrome. Arterial'naya Gipertenziya 2003; 9(5): 160-163. Russian (Мычка В.Б., Сергиенко В.Б., Г орностаев В.В. и др. Влияние терапии бисопрололом на перфузию головного мозга у больных с метаболическим синдромом. Артериальная Гипертензия 2003; 9(5): 160-163).Smith C., Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther 1999;13(2):123-126.Smith C., Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther 1999;13(2):123-126.Superko H.R., Haskell W.L., Krauss R.M. Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Atherosclerosis 1993;101(1):1-8.Superko H.R., Haskell W.L., Krauss R.M. Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Atherosclerosis 1993;101(1):1-8.Fogari R., Zoppi A., Pasotti C. et al. Plasma lipids during chronic antihypertensive therapy with different beta-blockers. J Cardiovasc Pharmacol 1989;14(Suppl 7):S28-32.Fogari R., Zoppi A., Pasotti C. et al. Plasma lipids during chronic antihypertensive therapy with different beta-blockers. J Cardiovasc Pharmacol 1989;14(Suppl 7):S28-32.Weiner L, Frithz G. Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension. J Cardiovasc Pharmacol 1986;8(Suppl 11):S106-112.Weiner L, Frithz G. Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension. J Cardiovasc Pharmacol 1986;8(Suppl 11):S106-112.Frithz G., Weiner L. Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cho- lesterol in patients with essential hypertension. J Cardiovasc Pharmacol 1986;8(Suppl 11):S134-138.Frithz G., Weiner L. Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cho- lesterol in patients with essential hypertension. J Cardiovasc Pharmacol 1986;8(Suppl 11):S134-138.

The authors declare that there are no conflicts of interest present.